BHBrian Hu

Brian Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brian Hu has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mitomycin Gel for the Pyelocaliceal System in Patients With Urinary Diversion: First Reported Cases and Operative Technique

    by Kai Wen Cheng, Grant Sajdak, Ala′A Farkouh, Sikai Song, Brian Hu

    Purpose: Mitomycin gel for the pyelocaliceal system (UGN‐101) is an approved kidney‐sparing therapy for upper tract urothelial carcinoma (UTUC). Little to no data exist on its safety and efficacy in patients with a history of urinary diversion. We report our experience with overcoming the anatomical challenges of UGN‐101 instillation in patients with UTUC and prior history of radical cystectomy with urinary diversion. Materials and Methods: Retrospective review was performed on all patients with pre‐existing urinary diversion who underwent UGN‐101 instillation for management of UTUC at a single academic institution. Surgical techniques for instillation are described, and the clinical course, including complications and disease status, are reported. Results: Two patients met inclusion criteria. One patient had carcinoma in situ in the renal pelvis and was treated with antegrade instillation via nephrostomy tube at an infusion clinic. The second patient had multifocal disease in the renal pelvis and the distal ureter and was treated with targeted antegrade instillation using an end‐hole catheter. Both patients experienced infectious complications, and one had a ureteral stricture that resolved without intervention. No diversion‐related complications were observed. Both patients are disease‐free at last follow‐up (10 months) on endoscopy and biopsy, although one patient required systemic immunotherapy. Conclusions: Our series highlights the potential role of UGN‐101 in patients with UTUC and pre‐existing urinary diversion. Antegrade instillation of UGN‐101 can be tailored to specific disease locations and should be considered for patients with a history of urinary diversion who are not candidates for extirpative surgery.

  • Open Access

    Penile mass with a past: Tertiary syphilis presenting as a penile gumma

    by Gabriel E. Martin, Sharon Wang, Nolan S. Maloney, Dan Xu, Herbert Ruckle, Martin R. Hofmann, Brian R. Hu

  • Paratesticular Tumors: A Systematic Review and Proposed Risk-Based Management Algorithm

    by Daniel Jhang, Kirulus Amin, Ala’A Farkouh, Eli Eshaghian, Muhannad Alsyouf, Brian Hu


  • Open Access

    Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel

    by Phillip M. Pierorazio, Nir Kleinmann, Ahmad Shabsigh, Brian Hu, Jay D. Raman, Hristos Kaimakliotis, Alexander Sankin, Nirmish Singla, Andrew Meads, Brent Burger, et al.

    To evaluate long-term outcomes of primary chemoablation using a mitomycin reverse thermal gel (UGN-101) in patients with low-grade upper tract urothelial carcinoma. Patients who participated in the OLYMPUS trial (TC-UT-03, NCT02793128) and achieved a complete response after 6 weekly doses of UGN-101 were followed up to 12 months after initial complete response. Those with complete response at study completion were eligible for long-term follow-up for up to 5 years or until disease recurrence, progression, or death. Of the 71 patients enrolled in the OLYMPUS trial, 42 patients achieved complete response 4-6 weeks after completing ≥1 instillation of UGN-101. Amongst the 41 patients followed after initial complete response, median follow-up was 28.1 months (95% CI 13.1, 57.5), and median duration of response was 47.8 months (95% CI 13.0, not estimable).Twenty patients (49%) had long-term follow-up (median 53.3 months [95% CI 27.9, 65.3]). Seventy-five percent of patients had no evidence of recurrence at last follow-up, with median duration of response not estimable (95% CI 43.5, not estimable) due to a low event rate. Primary intracavitary chemoablation with UGN-101 for low-grade upper tract urothelial carcinoma is associated with favorable long-term durability.


  • Open Access

    Genitourinary Cancer Care in Low- and Middle-Income Countries: Disparities in Incidence and Access to Care

    by Kanha Shete, Joshua Ghoulian, Brian Hu, Muhannad Alsyouf

    Despite the considerable global burden of urologic malignancies, Low- and middle-income countries (LMICs) often encounter significant challenges in caring for patients with urologic malignancies. Several interrelated factors impact cancer care in LMICs, which face significant challenges that hinder effective diagnosis, treatment, and management of disease. Socioeconomic and healthcare infrastructure limitations are fundamental issues leading to the disparity observed in cancer care across the globe. This review aims to evaluate the challenges and disparities in access to comprehensive urologic care in LMICs, emphasizing the impact of such global disparities on incidence rates, timely diagnoses, and access to comprehensive care as it relates to prostate, kidney, and bladder cancers.


  • Open Access

    Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)

    by Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc Bjurlin, Gordon Brown, Pencho Genov, Dimitar Shishkov, Alexandre Khuskivadze, Tosho Ganev, et al.

    Low-grade intermediate-risk nonmuscle-invasive bladder cancer is a chronic illness commonly treated by repetitive transurethral resection of bladder tumor. We compared the efficacy and safety of intravesical chemoablation with UGN-102 (a reverse thermal gel containing mitomycin), with or without subsequent transurethral resection of bladder tumor, to transurethral resection of bladder tumor alone in patients with low-grade intermediate-risk nonmuscle-invasive bladder cancer. This prospective, randomized, phase 3 trial recruited patients with new or recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer to receive initial treatment with either UGN-102 once weekly for 6 weeks or transurethral resection of bladder tumor. Patients were followed quarterly by endoscopy, cytology, and for-cause biopsy. The primary end point was disease-free survival. All patients were followed for adverse events. Trial enrollment was halted by the sponsor to pursue an alternative development strategy after 282 of a planned 632 patients were randomized to UGN-102 ± subsequent transurethral resection of bladder tumor (n=142) or transurethral resection of bladder tumor monotherapy (n=140), rendering the trial underpowered to perform hypothesis testing. Patients were predominantly male and ≥65 years of age. Tumor-free complete response 3 months after initial treatment was achieved by 92 patients (65%) who received UGN-102 and 89 patients (64%) treated by transurethral resection of bladder tumor. The estimated probability of disease-free survival 15 months after randomization was 72% for UGN-102 ± transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (hazard ratio 0.45). The most common adverse events (incidence ≥10%) in the UGN-102 group were dysuria, micturition urgency, nocturia, and pollakiuria. Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation.


  • Multimodal Pain Control Utilizing Buprenorphine for Robotic Assisted Laparoscopic Prostatectomy: A Quality Improvement Comparison to Conventional Opioid Management

    by Mohammad Hajiha, Donna Lien, Jo Ann Johnson, Ivan Muchiutti, Jasmine Sran, Alexandra Vacaru, Akin S. Amasyali, Leonard Soloniuk, Kanha Shete, Sonia Wraich, et al.

    Introduction:This study investigated the effectiveness of buprenorphine as an alternative to the use of conventional opioids perioperatively in an effort to help mitigate the impact of the use of perioperative conventional opioids for patients undergoing robotic-assisted laparoscopic prostatectomy.Methods:Outcomes of patients with localized prostate cancer undergoing robotic-assisted laparoscopic prostatectomy were examined before and after implementation of novel quality improvement study that included receiving buprenorphine compared to conventional opioids for pain control intraoperatively and postoperatively. The primary end point was adequate pain control with secondary end points being analgesic consumption at home, opioid-related side effects, and patient satisfaction.Results:When analyzing the secondary end point of oral morphine milligram equivalents, the buprenorphine group received significantly less morphine milligram equivalent compared to the conventional opioid group (15.19 vs 47.91, P = .006). The buprenorphine group also had lower reported pain scores at discharge (4.3; scale 1-10) compared to the conventional opioid group (5.4), though this did not reach significance (P = .069). In the buprenorphine group, 76.9% strongly agreed that their pain was adequately controlled in the hospital compared to 57.5% of the conventional opioid group (P = .223). There was no difference in overall satisfaction at postoperative day 5 (P = .358).Conclusions:Our study demonstrates buprenorphine's analgesic capabilities to maintain adequate pain control and patient satisfaction compared to conventional opioids during robotic-assisted laparoscopic prostatectomy, while decreasing perioperative opioid use.